Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 19/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.56 |
| ▸ | BCL2 | P10415 | 1/20 | 0.52 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.49 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2717464 | 1.00 | PIK3CD (0.59) | PIK3CDPIK3CGPIK3CBPIK3CABCL2 | |
| SCHEMBL15437024 | 1.00 | PIK3CD (0.59) | PIK3CDPIK3CGPIK3CBPIK3CABCL2 | |
| SCHEMBL2718843 | 0.91 | PIK3CD (0.56) | PIK3CDPIK3CGPIK3CBPIK3CABCL2 | |
| SCHEMBL2719584 | 0.90 | PIK3CD (0.57) | PIK3CDPIK3CGPIK3CBPIK3CABCL2 | |
| SCHEMBL4098550 | 0.90 | PIK3CD (0.57) | PIK3CDPIK3CGPIK3CBPIK3CABCL2 | |
| SCHEMBL15437109 | 0.90 | PIK3CD (0.57) | PIK3CDPIK3CGPIK3CBPIK3CABCL2 | |
| SCHEMBL4104277 | 0.88 | PIK3CD (0.49) | PIK3CDPIK3CGPIK3CBPIK3CABCL2 | |
| SCHEMBL4101744 | 0.88 | PIK3CD (0.49) | PIK3CDPIK3CGPIK3CBPIK3CABCL2 | |
| SCHEMBL4093343 | 0.88 | PIK3CD (0.49) | PIK3CDPIK3CGPIK3CBPIK3CABCL2 | |
| SCHEMBL2720230 | 0.87 | PIK3CD (0.63) | PIK3CDPIK3CGPIK3CBPIK3CABCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140031355-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2014-01-30 | — | — | US | claimed |
| US-20140031355-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031355-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, SSB, MALT1 | PIK3CD 1672/4885PIK3CG 2394/4885PIK3CB 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.